# A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)

> **NCT04771897** · PHASE1 · TERMINATED · sponsor: **Bexion Pharmaceuticals, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant

## Interventions

- **DRUG:** BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance
- **DRUG:** BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations

## Key facts

- **NCT ID:** NCT04771897
- **Lead sponsor:** Bexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-24
- **Primary completion:** 2024-10-04
- **Final completion:** 2024-10-04
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the anticipated enrollment goal. Justification for this decision is due to slow enrollment and the competitive landscape of the indication.
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04771897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04771897, "A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04771897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*